Abstract:Objective. In the development of many tumors, IPO5, as a member of the nuclear transporter family, exerts a significant function. Also, IPO5 is used as a therapeutic target for tumors based on some reports. By studying IPO5 expression in esophageal cancer tissues, the mechanism associated with IPO5 improving esophageal cancer development was explored in this study. Methods. To gain differentially expressed genes, this study utilized mRNA microarray and TCGA database for comprehensive analysis of esophageal cancer tissues and normal esophageal cancer tissues, and then the differentially expressed gene IPO5 was screened by us. To assess esophageal cancer patients' prognosis, this study also applied the Kaplan-Meier analysis, and we also conducted the GSEA enrichment analysis to investigate IPO5-related signaling pathways. This study performed TISIDB and TIMER online analysis tools to study the correlation between IPO5 and immune regulation and infiltration. We took specimens of esophageal cancer from patients and detected the expression of IPO5 in tumor and normal tissues by immunohistochemistry. The IPO5 gene-silenced esophageal cancer cell model was constructed by lentivirus transfection. Through the Transwell invasion assay, CCK-8 assay, and cell scratch assay, this study investigated the effects of IPO5 on cell propagation, invasion, and transfer. What is more, we identified the influences of IPO5 on the cell cycle through flow cytometry and established a subcutaneous tumor-forming model in nude mice. Immunohistochemistry was used to verify the expression of KI-67, and this study detected the modifications of cell pathway-related proteins using Western blot and applied EMT-related proteins to explain the mechanism of esophageal cancer induced by IPO5. Results. According to database survival analysis, IPO5 high-expression patients had shorter disease-free survival than IPO5 low-expression patients. Compared to normal tissues, the IPO5 expression in cancer tissues was significantly higher in clinical trials ( P < 0.05 ). Through TISIDB and TIMER database studies, we found that IPO5 could affect immune regulation, and the age of IPO5 expression grows with the increase of immune infiltration level. The IPO5 expression in esophageal cancer cells was higher than normal, especially in ECA109 and OE33 cells ( P < 0.01 ). After knocking out IPO5 gene expression, cell proliferation capacity and invasion capacity were reduced ( P < 0.05 ) and decreased ( P < 0.01 ) in the IPO5-interfered group rather than the negative control group. The growth cycle of esophageal carcinoma cells was arrested in the G2/M phase after IPO5 gene silencing ( P < 0.01 ). Tumor-forming experiments in nude mice confirmed that after IPO5 deletion, the tumor shrank, the expression of KI67 decreased, the downstream protein expression level of the RAS pathway decreased after sh-IPO5 interference ( P < 0.01 ), and the level of EMT marker delined ( P < 0.05 ). Conclusion. In esophageal cancer, IPO5 is highly expressed and correlates with survival rate. Esophageal cancer cell growth and migration were significantly affected by the inhibition of IPO5 in vitro and in vivo. IPO5 mediates EMT using the RAS-ERK signaling pathway activation and promotes esophageal cancer cell development in vivo and in vitro.

Ectopic Ikaros expression positively correlates with lung cancer progression.

Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.

Ikaros Inhibits Proliferation And, Through Upregulation of Slug, Increases Metastatic Ability of Ovarian Serous Adenocarcinoma Cells

Downregulation of AZGP1 by Ikaros and Histone Deacetylase Promotes Tumor Progression Through the PTEN/Akt and CD44s Pathways in Hepatocellular Carcinoma.

Ikaros antagonizes DNA binding by STAT5 in pre-B cells

Pathogenesis and regulation of cellular proliferation in acute lymphoblastic leukemia - the role of Ikaros.

The Transcription Factor Ikaros Inhibits Cell Proliferation by Downregulating ANXA4 Expression in Hepatocellular Carcinoma.

Serine Phosphorylation by SYK is Critical for Nuclear Localization and Transcription Factor Function of Ikaros

SOX5 Predicts Poor Prognosis in Lung Adenocarcinoma and Promotes Tumor Metastasis Through Epithelial-Mesenchymal Transition

Regulation of Heterochromatin Landscape in T-Cell Acute Lymphoblastic Leukemia

Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance

[Role and Significance of Ikaros Family in the Development of Hematopoietic System -Review].

Critical roles of Ikaros and HDAC1 in regulation of heterochromatin and tumor suppression in T-cell acute lymphoblastic leukemia

IKBKE promotes the ZEB2-mediated EMT process by phosphorylating HMGA1a in glioblastoma

Ikaros is degraded by proteasome-dependent mechanism in the early phase of apoptosis induction.

The Abnormal Expression of IKZF1 Encoded Protein-Ikaros in B-ALL Children

IPO5 Mediates EMT and Promotes Esophageal Cancer Development through the RAS-ERK Pathway

Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia

KIF18A knockdown reduces proliferation, migration, invasion and enhances radiosensitivity of esophageal cancer

Iqgap3 Promotes Egfr-Erk Signaling and the Growth and Metastasis of Lung Cancer Cells

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase